Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms

Front Oncol. 2021 Sep 15:11:762928. doi: 10.3389/fonc.2021.762928. eCollection 2021.

Ken-Hong Lim^{1

2}, Shinobu Matsuura³, Bing Xu^{4

5}

¹ Division of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei City, Taiwan.
² Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
³ Department of Medicine-Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, United States.
⁴ Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
⁵ Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China.

No abstract available

Keywords: CALR; MPL; chronic myeloid leukemia; myeloproliferative neoplasms; tyrosine kinase inhibitor.

Publication types